Edition:
India

DexCom Inc (DXCM.OQ)

DXCM.OQ on NASDAQ Stock Exchange Global Select Market

208.37USD
15 Nov 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$208.37
Open
$203.84
Day's High
$208.38
Day's Low
$202.18
Volume
320,246
Avg. Vol
293,879
52-wk High
$208.38
52-wk Low
$105.05

Latest Key Developments (Source: Significant Developments)

Court Rules That The Patents Asserted Against Dexcom Cgm Systems Are Invalid
Saturday, 24 Aug 2019 

Aug 23 (Reuters) - DexCom Inc ::COURT RULES THAT THE PATENTS ASSERTED AGAINST DEXCOM CGM SYSTEMS ARE INVALID.DEXCOM - U.S. DISTRICT COURT FOR DISTRICT OF OREGON GRANTED MOTION INVALIDATING ASSERTED CLAIMS IN 2 PATENTS AGAINST IT BY WAVEFORM TECHNOLOGIES, UNIT OF AGAMATRIX.  Full Article

Dexcom Says Chairman, President & CEO Kevin Sayer's FY 2018 Total Compensation Was $9.55 Million
Saturday, 20 Apr 2019 

April 19 (Reuters) - DexCom Inc ::DEXCOM INC SAYS CHAIRMAN, PRESIDENT & CEO KEVIN SAYER'S FY 2018 TOTAL COMPENSATION WAS $9.55 MILLION VERSUS $7.92 MILLION IN FY 2017 - SEC FILING.DEXCOM INC SAYS FOR 2018, RATIO OF ANNUAL TOTAL COMPENSATION OF CEO TO MEDIAN OF ANNUAL TOTAL COMPENSATION OF ALL EMPLOYEES IS 118:1.  Full Article

Dexcom G6 CGM System Receives Health Canada Approval
Friday, 22 Feb 2019 

Feb 22 (Reuters) - DexCom Inc ::DEXCOM G6® CGM SYSTEM RECEIVES HEALTH CANADA APPROVAL.G6 COMMERCIAL LAUNCH IN CANADA IS PLANNED FOR LATE 2019.  Full Article

Dexcom Sees FY 2019 Revenue Of About $1.175 Bln To $1.225 Bln
Monday, 7 Jan 2019 

Jan 7 (Reuters) - DexCom Inc ::DEXCOM REPORTS RECORD PRELIMINARY, UNAUDITED REVENUE FOR THE FOURTH QUARTER AND FISCAL YEAR 2018 AND PROVIDES INITIAL 2019 OUTLOOK.SEES FY 2019 REVENUE ABOUT $1.175 BILLION TO $1.225 BILLION.FY2019 REVENUE VIEW $1.18 BILLION -- REFINITIV IBES DATA.EXPECTS PRELIMINARY, UNAUDITED REVENUE FOR Q4 ENDED DECEMBER 31, 2018 TO EXCEED $331 MILLION.FOR FISCAL 2018, TOTAL PRELIMINARY, UNAUDITED REVENUE IS EXPECTED TO EXCEED $1.025 BILLION, AN INCREASE OF MORE THAN 42% OVER 2017..Q4 REVENUE VIEW $284.8 MILLION -- REFINITIV IBES DATA.FY2018 REVENUE VIEW $976.6 MILLION -- REFINITIV IBES DATA.  Full Article

Dexcom Prices Offering Of $750.0 Mln Of 0.75% Convertible Senior Notes
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - DexCom Inc ::DEXCOM PRICES OFFERING OF $750.0 MILLION OF 0.75% CONVERTIBLE SENIOR NOTES.DEXCOM INC - PRICES OFFERING OF $750.0 MILLION OF 0.75% CONVERTIBLE SENIOR NOTES DUE 2023.  Full Article

Dexcom Announces Proposed Offering Of $750 Mln Of Convertible Senior Notes
Tuesday, 27 Nov 2018 

Nov 26 (Reuters) - DexCom Inc ::DEXCOM ANNOUNCES PROPOSED OFFERING OF $750 MILLION OF CONVERTIBLE SENIOR NOTES.DEXCOM - INTENDS TO OFFER, SUBJECT TO MARKET CONDITIONS AND OTHER FACTORS, $750 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2023.DEXCOM INC - INTENDS TO GRANT INITIAL PURCHASERS OF NOTES A 13-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $100 MILLION AGGREGATE PRINCIPAL AMOUNT OF NOTES.  Full Article

DexCom Inc-Collaboration & License Agreement With Verily Life Sciences Shall Continue Until Dec. 31, 2028
Wednesday, 21 Nov 2018 

Nov 20 (Reuters) - Alphabet Holding Company Inc [RIC:RIC:ALHC.UL]::DEXCOM INC - COLLABORATION AND LICENSE AGREEMENT WITH VERILY LIFE SCIENCES SHALL CONTINUE UNTIL DECEMBER 31, 2028.DEXCOM INC - AGREEMENT SHALL BE EXTENDED UNTIL DECEMBER 31, 2033 UPON ACHIEVEMENT OF FIRST REVENUE MILESTONE EVENT & PAYMENT BY CO TO VERILY.  Full Article

Dexcom Files For Potential Mixed Shelf Offering Size Not Disclosed
Wednesday, 21 Nov 2018 

Nov 20 (Reuters) - DexCom Inc ::DEXCOM INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED .  Full Article

Dexcom And Verily Amend Collaboration And License Agreement
Wednesday, 21 Nov 2018 

Nov 20 (Reuters) - DexCom Inc ::DEXCOM AND VERILY AMEND COLLABORATION AND LICENSE AGREEMENT.DEXCOM INC - AMENDMENT INTENDED TO REINFORCE JOINT PRODUCT DEVELOPMENT TARGETS, ACCELERATE DEXCOM'S EFFORTS IN TYPE 2 DIABETES.DEXCOM INC - ROYALTY PAYMENTS SET FORTH IN ORIGINAL AGREEMENT HAVE BEEN ELIMINATED IN AMENDED AGREEMENT.DEXCOM INC - FOCUS SHIFTS TO COMMERCIALIZING SECOND GENERATION OFFERING.DEXCOM INC - WILL MAKE AN INITIAL PAYMENT OF $250 MILLION IN SHARES OF ITS COMMON STOCK.DEXCOM INC - DEXCOM WILL NOT OWE ANY ROYALTIES PURSUANT TO TERMS OF AMENDED AGREEMENT.DEXCOM INC - DEXCOM MAY MAKE UP TO $275 MILLION OF MILESTONE PAYMENTS IN SHARES OF ITS COMMON STOCK.DEXCOM - UNDER AGREEMENT, MILESTONE PAYMENTS OF UP TO $280 MILLION MAY BECOME DUE & PAYABLE BY CO UPON ACHIEVEMENT OF FUTURE PRODUCT LAUNCH, REVENUE MILESTONES.DEXCOM INC - FOR VERILY'S ONDUO FRANCHISE, CO TO BE PREFERRED CGM DEVICE SUPPLIER INTO ONDUO'S TYPE 2 DIABETES MANAGEMENT PROGRAM.DEXCOM INC - DEXCOM AND VERILY HAVE EXPANDED OPTIONS TO COLLABORATE ON DEVELOPMENT OF ADDITIONAL PRODUCTS AND SOFTWARE PERTAINING TO DEXCOM'S PRODUCTS.  Full Article

Agamatrix Says Judge Issued Order To Dexcom To Pay Co Its Costs Defending Against Case Since August 1, 2017
Tuesday, 5 Jun 2018 

June 5 (Reuters) - DexCom Inc ::AGAMATRIX - PREVAILING OUTCOME IN RETALIATORY PATENT INFRINGEMENT LAWSUIT BROUGHT BY DEXCOM INC.AGAMATRIX - JUDGE ISSUED ORDER IN MAY ORDERING DEXCOM TO PAY AGAMATRIX ITS COSTS, ATTORNEYS' FEES, EXPENSES DEFENDING AGAINST CASE SINCE AUGUST 1, 2017.AGAMATRIX - FEES CO IS REQUESTING ARE ABOUT $1.4 MILLION.  Full Article